Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple therapy takes on untreatable liver cancer

NCT ID NCT06882876

Disease control Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a combination of an experimental drug (JS014), an immunotherapy (toripalimab), and a targeted chemotherapy procedure (TACE) in 20 people with advanced liver cancer that cannot be surgically removed. The main goal is to check safety, but researchers will also measure how well the tumors shrink and how long patients live. Because it's a small, early study, results are not yet conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JS014 (an experimental drug) combined with toripalimab (an immunotherapy) and transarterial chemoembolization (a procedure that blocks blood flow to the tumor and delivers chemotherapy directly)
What this could lead to
If this works, it could point toward a more effective treatment for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is a very early, small trial with only 20 participants. The main goal is safety, not yet proof of effectiveness. Side effects from the drug combination or the procedure could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sign the informed consent form, voluntarily participate in this study, good compliance and follow-up cooperation. * Histologically or pathologically confirmed unresectable hepatocellular carcinoma; * Male or female patients aged 18-75 years; * Eastern Cooperative Oncology Group (ECOG) PS score of 0-1; * Child-Pugh score of ≤7; * BCLC/B stage; not previously treated with anti-cancer therapy; at least one measurable lesion (according to RECIST 1.1 criteria). * Sufficient organ function in vital organs (excluding serious functional impairment in the heart, lung, liver, kidney, bone marrow, nervous system, and endocrine systems). Exclusion Criteria: * Diagnosed with fibrolamellar carci-noma of liver, intrahepatic cholangiocarcinoma, and mixed carcinoma; * Within 28 days prior to the start of the study, the participant received treatment with another investigational drug or participated in another clinical study for a different therapeutic indication.; * Based on the investigator's judgment, the patient is expected to live for less than 12 weeks; * Uncontrolled pleural effusion, pericardial effusion, or ascites of moderate volume or more; * Current or past history of central nervous system metastasis; * Have a history of psychotropic drug abuse or drug use; * Hereditary or acquired tendency towards bleeding and thrombosis, a thromboembolic event occurred within the past 6 months; * Have a history of severe allergy to any monoclonal antibody, Toripalimab , JS014 and other ingredients of this study; * Pregnant or breastfeeding women; * Subjects with other factors that, in the judgment of the investigator, may cause the study to be prematurely terminated.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xiangya Hospital

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.